The combination treatment with both TMAO and CFT073 had significant additive effects on the release of PD-L1 and STAMBP and synergistic effects on the release of CDCP1, uPA, AXIN1, MMP-10, and CD40 compared to CFT073 infection alone (Figure 3). The gene discussed is CDCP1; the disease is infection.